BioVentrix seeks to sew up 60% of heart failure population
This article was originally published in Clinica
Executive Summary
A privately-backed US company is rolling out in Europe a less invasive surgical treatment for heart failure that has proven effective in arresting progression of the disease and improving the patient’s quality of life.